AMEDISYS INC (AMED) Stock News
NASDAQ:AMED - Nasdaq - US0234361089 - Common Stock - Currency: USD
AMED Latest News, Press Relases and Analysis
BrightSpring's Care Ratings Climb: Is Its Lead Sustainable?
BTSG boosts care quality with tech upgrades, earning top ratings and patient satisfaction across all segments.
AMED or CHE: Which Is the Better Value Stock Right Now?
AMED vs. CHE: Which Stock Is the Better Value Option?
Mentions: CHE
Amedisys (AMED) Down 0.8% Since Last Earnings Report: Can It Rebound?
Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Are Medical Stocks Lagging Amedisys (AMED) This Year?
Here is how Amedisys (AMED) and BrightSpring Health Services, Inc. (BTSG) have performed compared to their sector so far this year.
Mentions: BTSG
UnitedHealth, Amedisys reach new deal to sell home health and hospice locations if merger approved
The sales are contingent on the closure of UnitedHealth’s acquisition of Amedisys, which has been held up after the Department of Justice sued to block the deal last year.
Compared to Estimates, Amedisys (AMED) Q1 Earnings: A Look at Key Metrics
Although the revenue and EPS for Amedisys (AMED) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Amedisys (AMED) Tops Q1 Earnings Estimates
Amedisys (AMED) delivered earnings and revenue surprises of 10.62% and 0%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: EHC
Amedisys Reports First Quarter 2025 Financial Results
BATON ROUGE, La., April 23, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period ended...
Amedisys (AMED) Earnings Expected to Grow: Should You Buy?
Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: DGX
Novartis (NVS) Unleashes $23BN Strategic Investment Masterstroke
European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a major U.S. investment. The $200 billion pharma company intends to invest $23 billion in U.S.-based manufacturing to conduct research and development and produce all its major drugs stateside. Judging by Novartis’ stock performance in the days following the news, the market signaled its approval. Donald Trump is likely to be delighted, too. Novartis’ latest move is a reactiv
Amedisys Reports Fourth Quarter and Year End 2024 Financial Results
BATON ROUGE, La., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period and...
Amedisys Honors 47 Employees With Annual Spirit of Excellence Award
BATON ROUGE, La., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice and high-acuity care...
3 Stocks to Gain From Trump’s Family Caregiver Tax Credits
President Trump has spoken about implementing a family caregiver tax credit during his presidential campaign to ease the burden on caregivers, here's who gains.
UnitedHealth Group Q4 Earnings Preview: First Report Since Insurance CEO's Murder Comes With Questions On Company's Future
UnitedHealth shares a quarterly report for the first time since the death of insurance unit leader Brian Thompson. A look at the estimates and key items to watch.
UnitedHealth Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Mentions: UNH
UnitedHealth, Amedisys Extend Window to Finish $3.3 Billion Deal
UnitedHealth Group Inc. and Amedisys Inc. gave themselves more time to complete a $3.3 billion deal for the insurer to purchase the home-health provider that’s been challenged by the government.
Mentions: UNH
US Justice Department Preps Suit Over UnitedHealth-Amedisys Deal
The US Justice Department is moving to block UnitedHealth Group Inc.’s $3.3 billion purchase of Amedisys Inc. over concerns the deal would harm competition in the market for home-health services, according to people familiar with the matter.
Mentions: UNH
Amedisys Reports Third Quarter 2024 Financial Results
BATON ROUGE, La., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and nine-month...
UnitedHealth to Make Last Push for DOJ Blessing on Amedisys Deal
UnitedHealth Group Inc. and Amedisys Inc. representatives are slated to meet with top Justice Department antitrust enforcers next week in a last-ditch effort to persuade the agency not to challenge their proposed tie-up, according to people familiar with the matter.
Mentions: UNH
Amedisys has earned the 2023 SHPBest™ Patient Satisfaction Awards
BATON ROUGE, La., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice and high-acuity care in...